Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

RADAI-5 and electronic monitoring tools.

Leeb BF, Brezinschek HP, Rintelen B.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5 Suppl 101):S5-S10. Epub 2016 Oct 18. Review.

2.

A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study.

Stradner MH, Dejaco C, Brickmann K, Graninger WB, Brezinschek HP.

Arthritis Res Ther. 2016 Aug 24;18:190. doi: 10.1186/s13075-016-1091-1.

3.

Is the state of health of rheumatoid arthritis patients receiving adequate treatment, predictable? - Results of a survey.

Puchner R, Brezinschek HP, Fritz J, Herold M, Mustak M, Nothnagl T, Puchner SE, Studnicka-Benke A, Leeb BF.

BMC Musculoskelet Disord. 2015 May 6;16:109. doi: 10.1186/s12891-015-0567-5.

4.

Patient-centered psoriatic arthritis (PsA) activity assessment by Stockerau Activity Score for Psoriatic Arthritis (SASPA).

Leeb BF, Haindl PM, Brezinschek HP, Mai HT, Deutsch C, Rintelen B.

BMC Musculoskelet Disord. 2015 Apr 1;16:73. doi: 10.1186/s12891-015-0512-7.

5.

RADAI-5 to monitor rheumatoid arthritis.

Leeb BF, Haindl PM, Brezinschek HP, Nothnagl T, Rintelen B.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-55-8. Epub 2014 Oct 30.

PMID:
25365090
6.

Quality of care of rural rheumatoid arthritis patients in Austria.

Puchner R, Brezinschek HP, Herold M, Nothnagl T, Studnicka-Benke A, Fritz J, Leeb BF.

Wien Klin Wochenschr. 2014 Jun;126(11-12):360-7. doi: 10.1007/s00508-014-0540-6. Epub 2014 Mar 28.

PMID:
24676628
7.

Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen.

Moazedi-Fuerst FC, Kielhauser SM, Brickmann K, Hermann J, Lutfi A, Meilinger M, Brezinschek HP, Graninger WB.

Scand J Rheumatol. 2014;43(3):257-8. doi: 10.3109/03009742.2013.869617. Epub 2014 Mar 11. No abstract available.

8.

Remission in rheumatoid arthritis: a comparison of the 2 newly proposed ACR/EULAR remission criteria with the rheumatoid arthritis disease activity index-5, a patient self-report disease activity index.

Rintelen B, Sautner J, Haindl P, Mai H, Brezinschek HP, Leeb BF.

J Rheumatol. 2013 Apr;40(4):394-400. doi: 10.3899/jrheum.120952. Epub 2013 Feb 1.

PMID:
23378466
9.

B lymphocyte-typing for prediction of clinical response to rituximab.

Brezinschek HP, Rainer F, Brickmann K, Graninger WB.

Arthritis Res Ther. 2012 Jul 6;14(4):R161. doi: 10.1186/ar3901.

10.

Superior specificity of anti-citrullinated peptide antibodies in patients with chronic lymphocytic leukemia and arthritis.

Brickmann K, Brezinschek RI, Yazdani-Biuki B, Graninger WB, Brezinschek HP.

Clin Exp Rheumatol. 2010 Nov-Dec;28(6):888-91. Epub 2011 Jan 3.

PMID:
21205465
11.

The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project.

Leeb BF, Böttcher E, Brezinschek HP, Czerwenka C, Herold M, Hitzelhammer H, Mayrhofer F, Puchner R, Rainer F, Rintelen B, Schirmer M, Stuby U, Bröll H.

Clin Rheumatol. 2010 Feb;29(2):167-74. doi: 10.1007/s10067-009-1304-y. Epub 2009 Nov 11.

12.

The functional promoter polymorphism of the coagulation factor XII gene is not associated with peripheral arterial disease.

Yazdani-Biuki B, Krippl P, Brickmann K, Fuerst F, Langsenlehner U, Paulweber B, Pilger E, Wascher TC, Brezinschek HP, Renner W.

Angiology. 2010 Feb;61(2):211-5. doi: 10.1177/0003319709337305. Epub 2009 Jul 21.

PMID:
19625260
13.

[Mechanisms of muscle pain : significance of trigger points and tender points].

Brezinschek HP.

Z Rheumatol. 2008 Dec;67(8):653-4, 656-7. doi: 10.1007/s00393-008-0353-y. Review. German.

PMID:
19015861
14.

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.

Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, Goel N, Brezinschek HP, Innes A, Strand V.

Ann Rheum Dis. 2009 Jun;68(6):805-11. doi: 10.1136/ard.2008.099291. Epub 2008 Nov 17.

15.

The Glu228Ala polymorphism in the ligand-binding domain of death receptor 4 is not associated with rheumatoid arthritis.

Yazdani-Biuki B, Brickmann K, Langsenlehner U, Renner W, Truschnig M, Krippl P, Fürst F, Graninger WB, Brezinschek HP.

Ann Rheum Dis. 2008 Jul;67(7):1053-4. doi: 10.1136/ard.2007.086124. No abstract available.

PMID:
18556450
16.

Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate.

Brezinschek HP, Hofstaetter T, Leeb BF, Haindl P, Graninger WB.

Curr Opin Rheumatol. 2008 May;20(3):295-9. doi: 10.1097/BOR.0b013e3282ffdeca. Review.

PMID:
18388521
17.

Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy.

Martinez-Gamboa L, Brezinschek HP, Burmester GR, Dörner T.

Autoimmun Rev. 2006 Aug;5(7):437-42. Epub 2006 Mar 9. Review.

PMID:
16920569
18.

Relapse of diabetes after interruption of chronic administration of anti-tumor necrosis factor-alpha antibody infliximab: a case observation.

Yazdani-Biuki B, Mueller T, Brezinschek HP, Hermann J, Graninger W, Wascher TC.

Diabetes Care. 2006 Jul;29(7):1712-3. No abstract available.

PMID:
16801612
19.

The MHC2TA -168A>G gene polymorphism is not associated with rheumatoid arthritis in Austrian patients.

Yazdani-Biuki B, Brickmann K, Wohlfahrt K, Mueller T, März W, Renner W, Gutjahr M, Langsenlehner U, Krippl P, Wascher TC, Paulweber B, Graninger W, Brezinschek HP.

Arthritis Res Ther. 2006;8(4):R97.

20.

Treatment of rheumatoid arthritis in the 21st century: targeting B-lymphocytes.

Brezinschek HP, Brickmann K, Yazdani-Biuki B, Dörner T, Graninger WB, Brezinschek RI.

Wien Med Wochenschr. 2006 Jan;156(1-2):61-7. Review.

PMID:
16465615
21.

Blockade of tumour necrosis factor {alpha} significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis.

Yazdani-Biuki B, Stadlmaier E, Mulabecirovic A, Brezinschek R, Tilz G, Demel U, Mueller T, Brickmann K, Graninger WB, Brezinschek HP.

Ann Rheum Dis. 2005 Aug;64(8):1224-6.

22.

Receptor revision and atypical mutational characteristics in clonally expanded B cells from the cerebrospinal fluid of recently diagnosed multiple sclerosis patients.

Monson NL, Brezinschek HP, Brezinschek RI, Mobley A, Vaughan GK, Frohman EM, Racke MK, Lipsky PE.

J Neuroimmunol. 2005 Jan;158(1-2):170-81.

PMID:
15589051
23.

Long term treatment of psoriatic arthritis with infliximab.

Yazdani-Biuki B, Wohlfahrt K, Mulabecirovic A, Mueller T, Hermann J, Graninger WB, Brezinschek HP, Brezinschek RI.

Ann Rheum Dis. 2004 Nov;63(11):1531-2; author reply 1532. No abstract available.

24.

Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab.

Yazdani-Biuki B, Stelzl H, Brezinschek HP, Hermann J, Mueller T, Krippl P, Graninger W, Wascher TC.

Eur J Clin Invest. 2004 Sep;34(9):641-2. No abstract available.

PMID:
15379764
25.

The role of CD40-CD40 ligand (CD154) interactions in immunoglobulin light chain repertoire generation and somatic mutation.

Monson NL, Foster SJ, Brezinschek HP, Brezinschek RI, Dörner T, Lipsky PE.

Clin Immunol. 2001 Jul;100(1):71-81.

PMID:
11414747
26.
27.
28.
29.

Pairing of variable heavy and variable kappa chains in individual naive and memory B cells.

Brezinschek HP, Foster SJ, Dörner T, Brezinschek RI, Lipsky PE.

J Immunol. 1998 May 15;160(10):4762-7.

30.

Comparable impact of mutational and selective influences in shaping the expressed repertoire of peripheral IgM+/CD5- and IgM+/CD5+ B cells.

Dörner T, Brezinschek HP, Foster SJ, Brezinschek RI, Farner NL, Lipsky PE.

Eur J Immunol. 1998 Feb;28(2):657-68.

31.

Delineation of selective influences shaping the mutated expressed human Ig heavy chain repertoire.

Dörner T, Brezinschek HP, Foster SJ, Brezinschek RI, Farner NL, Lipsky PE.

J Immunol. 1998 Mar 15;160(6):2831-41.

32.

Analysis of the human VH gene repertoire. Differential effects of selection and somatic hypermutation on human peripheral CD5(+)/IgM+ and CD5(-)/IgM+ B cells.

Brezinschek HP, Foster SJ, Brezinschek RI, Dörner T, Domiati-Saad R, Lipsky PE.

J Clin Invest. 1997 May 15;99(10):2488-501.

33.

Molecular mechanisms and selective influences that shape the kappa gene repertoire of IgM+ B cells.

Foster SJ, Brezinschek HP, Brezinschek RI, Lipsky PE.

J Clin Invest. 1997 Apr 1;99(7):1614-27.

34.

Analysis of the frequency and pattern of somatic mutations within nonproductively rearranged human variable heavy chain genes.

Dörner T, Brezinschek HP, Brezinschek RI, Foster SJ, Domiati-Saad R, Lipsky PE.

J Immunol. 1997 Mar 15;158(6):2779-89.

PMID:
9058813
35.

Expression of the beta 7 integrin by human endothelial cells.

Brezinschek RI, Brezinschek HP, Lazarovits AI, Lipsky PE, Oppenheimer-Marks N.

Am J Pathol. 1996 Nov;149(5):1651-60.

36.

Staphylococcal enterotoxin D functions as a human B cell superantigen by rescuing VH4-expressing B cells from apoptosis.

Domiati-Saad R, Attrep JF, Brezinschek HP, Cherrie AH, Karp DR, Lipsky PE.

J Immunol. 1996 May 15;156(10):3608-20.

PMID:
8621894
37.

Cytokine levels in the seminal plasma of infertile males.

Gruschwitz MS, Brezinschek R, Brezinschek HP.

J Androl. 1996 Mar-Apr;17(2):158-63.

38.

Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction.

Brezinschek HP, Brezinschek RI, Lipsky PE.

J Immunol. 1995 Jul 1;155(1):190-202.

PMID:
7602095
39.

Cell-type specific response of peripheral blood lymphocytes to methotrexate in the treatment of rheumatoid arthritis.

Wascher TC, Hermann J, Brezinschek HP, Brezinschek R, Wilders-Truschnig M, Rainer F, Krejs GJ.

Clin Investig. 1994 Jul;72(7):535-40.

PMID:
7981583
40.

Serum levels of interleukin-6 and tumour-necrosis-factor-alpha are not correlated to disease activity in patients with rheumatoid arthritis after treatment with low-dose methotrexate.

Wascher TC, Hermann J, Brezinschek R, Brezinschek HP, Wilders-Truschnig M, Rainer F, Krejs GJ.

Eur J Clin Invest. 1994 Jan;24(1):73-5.

PMID:
8187811
41.

Effects of cytokine application on glucocorticoid secretion in an animal model for systemic scleroderma.

Brezinschek HP, Gruschwitz M, Sgonc R, Moormann S, Herold M, Gershwin ME, Wick G.

J Autoimmun. 1993 Dec;6(6):719-33.

PMID:
8155253
42.

Increased immune activation during and after physical exercise.

Tilz GP, Domej W, Diez-Ruiz A, Weiss G, Brezinschek R, Brezinschek HP, Hüttl E, Pristautz H, Wachter H, Fuchs D.

Immunobiology. 1993 Jun;188(1-2):194-202.

PMID:
8104879
43.

Antinuclear antibody profile in UCD line 200 chickens: a model for progressive systemic sclerosis.

Gruschwitz MS, Shoenfeld Y, Krupp M, Gershwin ME, Penner E, Brezinschek HP, Wick G.

Int Arch Allergy Immunol. 1993;100(4):307-13.

PMID:
8386962
44.

Micrometastatic tumour cells in bone marrow in colorectal cancer.

Silly H, Samonigg H, Stöger H, Brezinschek HP, Wilders-Truschnig M.

Lancet. 1992 Nov 21;340(8830):1288. No abstract available.

PMID:
1359340
45.

Investigation of ACTH responses of chickens with autoimmune disease.

Herold M, Brezinschek HP, Gruschwitz M, Dietrich H, Wick G.

Gen Comp Endocrinol. 1992 Nov;88(2):188-98.

PMID:
1335939
46.

Involvement of the immune system in iodine deficient goiter.

Wilders-Truschnig MM, Leb G, Warnkross H, Langsteger W, Eber O, Dimal P, Brezinschek HP, Brezinschek R, Tiran A, Den Hartog MT, et al.

Thyroidology. 1992 Apr;4(1):53-5.

PMID:
1284335
47.

Analysis of the immune-encodrine feedback loop in the avian system and its alteration in chickens with spontaneous autoimmune thyroiditis.

Brezinschek HP, Faessler R, Klocker H, Kroemer G, Sgonc R, Dietrich H, Jakober R, Wick G.

Eur J Immunol. 1990 Oct;20(10):2155-9.

PMID:
2242753
48.

Chromatographically purified immunoglobulin G of endemic and sporadic goiter patients stimulates FRTL5 cell growth in a mitotic arrest assay.

Wilders-Truschnig MM, Drexhage HA, Leb G, Eber O, Brezinschek HP, Dohr G, Lanzer G, Krejs GJ.

J Clin Endocrinol Metab. 1990 Feb;70(2):444-52.

PMID:
1688867
49.

Spontaneous autoimmune thyroiditis: new therapeutic strategies.

Wick G, Dietrich H, Kroemer G, Brezinschek HP, Faessler R, Schuurs AH.

Immunol Ser. 1990;52:191-211. Review. No abstract available.

PMID:
2091780
50.

Thyroid growth promoting serum-IgG in endemic goiter.

Brezinschek HP, Wilders-Truschnig M, Leb G, Eber O, Dohr G, Lanzer G, Krejs GJ.

Acta Med Austriaca. 1990;17 Suppl 1:26-7.

PMID:
1975149

Supplemental Content

Loading ...
Support Center